Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

6.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Persistent CD4<sup>+</sup> T cell hyporesponsiveness during recovery from prolonged symptomatic SARS-CoV-2 infection.

Cellular immunology·2026
Same author

Serum proteomic atlas reveals distinct molecular signatures of lupus nephritis activity, chronicity, and treatment response.

bioRxiv : the preprint server for biology·2026
Same author

Deep profiling of lupus nephritis kidneys reveals dynamic changes in myeloid cells associated with disease progression.

Annals of the rheumatic diseases·2026
Same author

Clinical, Histologic, and Serological Predictors of Renal Function Loss in Lupus Nephritis.

Arthritis care & research·2026
Same author

Human hypofunctional NCF1 variant aggravates salivary gland immunopathology in Sjögren's disease by promoting switched memory B-cell recruitment and long-lived plasma cell differentiation.

Annals of the rheumatic diseases·2026
Same author

A population-scale atlas of blood and tissue in lupus nephritis.

bioRxiv : the preprint server for biology·2026
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Related Experiment Video

Updated: Apr 8, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.7K

Preclinical lupus.

Rebecka Bourn1, Judith A James

  • 1aArthritis and Clinical Immunology, Oklahoma Medical Research Foundation bOklahoma Clinical and Translational Science Institute; Departments of Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.

Current Opinion in Rheumatology
|July 1, 2015
PubMed
Summary
This summary is machine-generated.

Understanding early systemic lupus erythematosus (SLE) involves recognizing immune dysregulation before full classification. Early identification and intervention in SLE are crucial for better patient outcomes and therapeutic development.

More Related Videos

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

19.1K
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

1.5K

Related Experiment Videos

Last Updated: Apr 8, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.7K
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

19.1K
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

1.5K

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Systemic lupus erythematosus (SLE) development is preceded by a period of immune dysregulation and sub-threshold clinical manifestations.
  • Incomplete lupus erythematosus (ILE) shares features with SLE but has fewer symptoms, yet can lead to significant organ damage and mortality.

Purpose of the Study:

  • To review current and evolving concepts of the preclassification period of SLE.
  • To discuss clinical and mechanistic observations relevant to early SLE.
  • To explore potential strategies for early identification and intervention in SLE.

Main Methods:

  • Review of current literature on SLE and its early stages.
  • Analysis of clinical and mechanistic data from preclinical and incomplete lupus erythematosus.
  • Consideration of murine studies for potential therapeutic targets.

Main Results:

  • ILE patients exhibit antinuclear antibody seropositivity, arthritis, and immune/hematological disorders, with risks of pulmonary arterial hypertension and organ damage.
  • Recent classification criteria may redefine the 'preclinical SLE' period.
  • Murine models suggest T-helper/T-regulatory cell balance, PPARγ activity, and plasmacytoid dendritic cell pathways as potential early intervention targets.

Conclusions:

  • Improved understanding of early SLE stages aids in identifying high-risk individuals for prevention trials.
  • Enhanced knowledge can refine diagnostic testing for SLE.
  • Novel therapeutic targets for clinical SLE may emerge from studying early disease stages.